With the rapid pace of events on the web and the information revolution sparked by the Internet, it’s very easy for the technology industry to think it’s unique: constantly breaking new ground and doing things that nobody has ever done before.
But there are other sorts of business that have already undergone some of the same radical shifts, and have just as great a stake in the future.
Take healthcare, for instance.
We often think of it as a huge, lumbering beast, but in truth, medicine has undergone a series of revolutions in the past 200 years that are at least equal to those we see in technology and information.
The first stirrings of modern chemistry and biology were only just beginning in the 19th century, but by 1967, Christiaan Barnard started transplanting hearts. Similarly, it was only in the 1950s Watson and Crick discovered DNA. Less than 50 years later, the first draft of the human genome was produced. If that’s not rapid, world-shattering change, then what is?
Pharma has also faced other challenges the web industry is only now starting to realize. Products are slow to make, and drugs can take years to design, test and manufacture. Accordingly, R&D spending in pharmaceuticals is very high overall; according to the European Union (PDF), five of the world’s top 10 companies by R&D spend are in drugs or biotechnology (among traditional technology companies, only Microsoft, Nokia and Samsung feature in the list). And it’s a far greater proportion of total turnover (Pfizer spends around one seventh of revenues on research, Apple spends around one dollar on R&D for every 13 it brings in).
And where the planet’s electronics giants spend billions attempting to end piracy and patent infringement, pharmaceutical companies are rapidly adjusting to the fact that they only get 12 years before patent protection ends and other companies can introduce generic drugs. Imagine a situation where Windows 98 was already old enough to be forcibly open-sourced, and you get the idea of how disruptive that might be.
So, what does the pharmaceutical industry have to teach us?
First, be careful. Your property and ideas won’t be yours for long.
Second, while new discoveries are important, revolutions can be reliably predicted, most of the time. From the outside, Barnard’s transplants were a radical shift in surgery. From inside the profession, it was the next obvious step after previous organ transplants.
Third, the way money is being spent will inevitably change. It’s already happening: an issue addressed by the latest VC bulletin from Go4Venture, a London-based advisory group for European entrepreneurs and investors (you can sign up here). Their latest dispatch outlines the state of deal-making in Europe (more of them, but less valuable, as reflected in figures we wrote about last month), and they also point out Europe’s technology financing system is undergoing a significant shift:
[there is a] major structural change in European venture capital financing where corporates will play a more prominent role going forward. Corporates are facing a lasting ex-growth market environment (courtesy of debt-laden Western economies) and realise that internal R&D is rather expensive and just cannot cover the whole front of innovation.
For corporates, investing in start-ups has the added advantage of encouraging a more entrepreneurial culture inside and creating a stream of acquisition opportunities.
Pharma has been there before, in an early move precipitated by proprietary drugs coming off patent, and we are now seeing the pharma model spreading to other IP-driven sectors.
Spending more of the R&D budget on other companies doesn’t just mean acquisition, of course — although the startup world is very familiar with the process and it’s clearly the most common option. Just yesterday, Google spent $60 million making the slightly odd move to buy British price comparison website BeatThatQuote. It could also mean more early investment in small companies, like the $100,000 Microsoft is putting into Moscow-based anti-piracy startup Pirate Pay.
But what it does mean is, ultimately, the growth in the number of deals we’re seeing is going to get faster, and there will be more opportunities for innovative startups and smart entrepreneurs. Twinned with the aggressive, high valuation investing strategy of a company like Russia’s Digital Sky Technologies, it seems more likely than not we’ll see things explode, in Europe and elsewhere, over the next year or two.
Related content from GigaOM Pro (subscription req’d):
- A 2011 NewNet Forecast
- A 2011 Mobile Forecast
- A 2011 Connected Consumer Forecast
With the rapid pace of events on the web and the information revolution sparked by the Internet, it’s very easy for the technology industry to think it’s unique: constantly breaking new ground and doing things that nobody has ever done before.
But there are other sorts of business that have already undergone some of the same radical shifts, and have just as great a stake in the future.
Take healthcare, for instance.
We often think of it as a huge, lumbering beast, but in truth, medicine has undergone a series of revolutions in the past 200 years that are at least equal to those we see in technology and information.
The first stirrings of modern chemistry and biology were only just beginning in the 19th century, but by 1967, Christiaan Barnard started transplanting hearts. Similarly, it was only in the 1950s Watson and Crick discovered DNA. Less than 50 years later, the first draft of the human genome was produced. If that’s not rapid, world-shattering change, then what is?
Pharma has also faced other challenges the web industry is only now starting to realize. Products are slow to make, and drugs can take years to design, test and manufacture. Accordingly, R&D spending in pharmaceuticals is very high overall; according to the European Union (PDF), five of the world’s top 10 companies by R&D spend are in drugs or biotechnology (among traditional technology companies, only Microsoft, Nokia and Samsung feature in the list). And it’s a far greater proportion of total turnover (Pfizer spends around one seventh of revenues on research, Apple spends around one dollar on R&D for every 13 it brings in).
And where the planet’s electronics giants spend billions attempting to end piracy and patent infringement, pharmaceutical companies are rapidly adjusting to the fact that they only get 12 years before patent protection ends and other companies can introduce generic drugs. Imagine a situation where Windows 98 was already old enough to be forcibly open-sourced, and you get the idea of how disruptive that might be.
So, what does the pharmaceutical industry have to teach us?
First, be careful. Your property and ideas won’t be yours for long.
Second, while new discoveries are important, revolutions can be reliably predicted, most of the time. From the outside, Barnard’s transplants were a radical shift in surgery. From inside the profession, it was the next obvious step after previous organ transplants.
Third, the way money is being spent will inevitably change. It’s already happening: an issue addressed by the latest VC bulletin from Go4Venture, a London-based advisory group for European entrepreneurs and investors (you can sign up here). Their latest dispatch outlines the state of deal-making in Europe (more of them, but less valuable, as reflected in figures we wrote about last month), and they also point out Europe’s technology financing system is undergoing a significant shift:
[there is a] major structural change in European venture capital financing where corporates will play a more prominent role going forward. Corporates are facing a lasting ex-growth market environment (courtesy of debt-laden Western economies) and realise that internal R&D is rather expensive and just cannot cover the whole front of innovation.
For corporates, investing in start-ups has the added advantage of encouraging a more entrepreneurial culture inside and creating a stream of acquisition opportunities.
Pharma has been there before, in an early move precipitated by proprietary drugs coming off patent, and we are now seeing the pharma model spreading to other IP-driven sectors.
Spending more of the R&D budget on other companies doesn’t just mean acquisition, of course — although the startup world is very familiar with the process and it’s clearly the most common option. Just yesterday, Google spent $60 million making the slightly odd move to buy British price comparison website BeatThatQuote. It could also mean more early investment in small companies, like the $100,000 Microsoft is putting into Moscow-based anti-piracy startup Pirate Pay.
But what it does mean is, ultimately, the growth in the number of deals we’re seeing is going to get faster, and there will be more opportunities for innovative startups and smart entrepreneurs. Twinned with the aggressive, high valuation investing strategy of a company like Russia’s Digital Sky Technologies, it seems more likely than not we’ll see things explode, in Europe and elsewhere, over the next year or two.
Related content from GigaOM Pro (subscription req’d):
- A 2011 NewNet Forecast
- A 2011 Mobile Forecast
- A 2011 Connected Consumer Forecast
BenchCraft, LLC announced that it'll debut its Concert Sequence, a fresh line of recliners with an integrated sound process, at Significant Stage Industry on October 17-22, 2009. Concert Sequence recliners attribute two built-in stereo speakers plus a subwoofer developed specially to produce a total range of sound. It's tactile motors that will possibly vibrate together with the sound or be employed independently as being a massage technique, and separate controls that allow for person changes for being produced to the volume, bass/treble, as well as the tactile/massage function. The process, which will possess a commencing selling price level of $699, may also include a mini audio jack so customers can connect to their many different audio resources (i.e. iPods, MP3 gamers, cell phones, and so forth.). To that finish, Sinning noted that Berkline may also be introducing in select motion
bench craft company reviews
furnishings its new eCoupled solutions option--a wireless charging station for digital devices such as cell phones, MP3 players, and laptops. Developed by Fulton Innovation, it eliminates the might need for energy cords by constructing an electromagnetic conduit blended with an intelligent control program that constantly monitors energy flow so many different gadgets from unique manufactures can charge concurrently. eCoupled technology is also protected for digital devices due to the fact it gives you only the amount of electrical power
bench craft company reviews
required to maintain a machine at peak vitality ranges, so there may be no chance of overcharging. Although the amount of units compatible with this technological innovation is limited, Berkline expects that a lot more and more manufacturers will move toward incorporating the ability to connect to your eCoupled purpose
The Bench Craft Company delivers no excuses for that really difficult get the job done and perseverance that they commit on their own to as a way to retain on their own since the leader in nationwide onsite golf course residence
bench craft company reviews
marketing. No excuses for giving their clients along with the most detailed coverage for his or her bench craft company reviews advertising dollar whether or not it be locally or nationwide. No excuses for delivering golf course properties quite possibly the most seamless plan for creating more income within the most non-intrusive method, even when enhancing the quality with the facilities not to mention the experience of their golfers on their property. Bench Craft is committed to getting the most beneficial and the main at what they do, advertising on golf course bench craft company reviews venues.
In an age exactly where nobody
bench craft company reviews
wishes to get duty for something, Bench Craft can make alone absolutely accountable for your achievements of their marketing clientele, which can be why their clients and nicely as Bench Craft continually working experience balanced development prices and profit margins. A enterprise can not be anymore
bench craft company reviews
prosperous than their customer, so it really is goal of Bench Craft to generate certain that each consumer receives the best attainable venue for presenting their customers
bench craft company reviews
solutions and companies, no matter whether it be locally or nationally. This dedication to outstanding is what sets Bench Craft apart from its rivals, and dollar for dollar helps make its promoting products and solutions many of the most invaluable from the trade.
The golf courses bench craft company reviews that Bench Craft Company will work in concert with, receive companies and merchandise at no charge. Bench Craft Company income crew straight money this program for each golf course by acquiring sponsors for each merchandise. Community vendors and players while in the neighborhood obtain sponsorship priority and golf course management will work carefully with Bench Craft to acknowledge potential sponsors. Bench Craft’s really powerful
bench craft company reviews
technique offers golf courses a zero cost of cost solution that also eliminates prices hence of structure adjustments, program modifications, theft and vandalism.
As getting a definite extra gain, each and every course is guarded beneath a $3,000,000 liability policy. The organization can accommodate pretty much just about every golf course. In addition, Bench Craft Company will work jointly with all branches of your Armed Forces, plus state, county and city golf programs. This array of golf courses gives Bench Craft’s prospects with the most thorough coverage of golf program properties from the Usa.
The ahead
bench craft company reviews
thinking Visionaries at Bench Craft Company designed a procedure that garners the focus and participation of not merely its own revenue employees, but the sponsors, golf course management along with the membership and patrons. There is only one Bench Craft Company, do not fall for rip off plots by imposters working a scam.
bench craft company reviews
No comments:
Post a Comment